MedTrace Logo

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

NCT05570253 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-04-27

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

Conditions

Interventions

DRUG

Eribulin

Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

DRUG

SDX-7320

SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Sherry Shen, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05570253 on ClinicalTrials.gov